THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts. “Receiving the positive…
News Ticker
- [ September 28, 2023 ] TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting Los Angeles Biotech News
- [ September 28, 2023 ] Alfred Mann Foundation Rebrands as huMannity Medtec, Unveiling a Bold, Future-Focused Identity Los Angeles Biotech News
- [ September 28, 2023 ] Medical Laboratory Scientist – VIR Healthway – Santa Monica, CA Los Angeles Biotech Jobs
- [ September 28, 2023 ] New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint® Los Angeles Biotech News
- [ September 28, 2023 ] Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
